![]() |
John CahillDirector, Senior Consultant, Q&C,PharmaLex |
![]() |
Richard PhillipsPartner & Corporate Lawyer, VWV |
![]() |
Anna GeistDirector, Head of Regulatory & Special Projects, PharmaLex |
2021 started with stellar news as Sanofi agreed to acquire British biotech Kymab for around $1.45 billion. It is a chequered flag for the start of this seasons M&A activity for Life Sciences companies. Great expectations? This fast-growing sector comprises pharma, biotech, cell & gene therapy, medical device and diagnostics amongst all. Corporations must take expert legal and regulatory advice in addition to financial due diligence.
PharmaLex and VWV ponder legal and regulatory solutions for supporting M&A deals, takeovers, business moves, leveraging, spin-outs, carve-outs and strategic partnerships.